Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01492101 · ClinicalTrials.gov registry record · Phase 3
The BEACON Study (Breast Cancer Outcomes With NKTR-102)
A Phase 3 study, sponsored by Nektar Therapeutics.
- Completed
- Registry status
- Phase 3
- Development phase
- 852
- Enrollment target
NCT01492101 is a Phase 3 study that has completed, run by Nektar Therapeutics. The registered enrollment target is 852 participants.
The verdict
NCT01492101, a Phase 3 study, has completed, sponsored by Nektar Therapeutics.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 852 participants
- Enrollment target
Study Summary
The study is designed as an open-label, randomized, parallel, two arm, multicenter, international Phase 3 study in patients with recurrent or metastatic breast cancer previously treated with cytotoxic chemotherapy regimens. The primary study objective is to compare overall survival of patients who receive NKTR-102 given once every 21 days to patients who receive treatment of Physician's Choice selected from a list of seven single-agent intravenous therapies.
Interventions
- DRUG NKTR-102
- DRUG Treatment of Physician's Choice (TPC)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 852 participants |
| Start Date | 2011-12 |
| Est. Completion | 2016-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01492101
The ClinicalTrials.gov registry entry for NCT01492101 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 852 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Nektar Therapeutics, which has 37 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which NKTR-102 is the first listed.
NCT01492101 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01492101 about?
NCT01492101 is a clinical study titled "The BEACON Study (Breast Cancer Outcomes With NKTR-102)". The study is designed as an open-label, randomized, parallel, two arm, multicenter, international Phase 3 study in patients with recurrent or metastatic breast cancer previously treated with cytotoxic chemotherapy regimens. The primary study objective is to compare overall survival of patients who ...
What is the current status of trial NCT01492101?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 852 participants. The study started on 2011-12. Estimated completion is 2016-06.
What interventions are being tested in trial NCT01492101?
The interventions under investigation include: NKTR-102 (DRUG), Treatment of Physician's Choice (TPC) (DRUG).
Who is sponsoring clinical trial NCT01492101?
This trial is sponsored by Nektar Therapeutics, which has 37 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.